MS patients switch meds – will it work as well?
NCT ID NCT07235644
First seen Nov 19, 2025 · Last updated May 15, 2026 · Updated 30 times
Summary
This study looks at 184 people with relapsing-remitting multiple sclerosis who switched from the drug MabThera to a similar drug called Rixathon. Researchers want to see if the switch changes nerve damage, brain lesions, relapses, or disability. They will use existing medical records, blood tests, and MRI scans to compare outcomes before and after the switch.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS (MS) - RELAPSING-REMITTING are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Uppsala University Hospital
Uppsala, Sweden
Conditions
Explore the condition pages connected to this study.